埃克替尼联合安罗替尼或贝伐珠单抗治疗表皮生长因子受体敏感突变晚期非小细胞肺癌的效果及预后分析

doi:10.3969/j.issn.1006-6233.2023.12.028

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1232 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 探讨埃克替尼联合安罗替尼或贝伐珠单抗治疗表皮生长因子受体(EGFR)敏感突变晚期非小细胞肺癌(NSCLC)的效果及预后。方法: 回顾性分析2019年9月至2021年2月107例EGFR敏感突变晚期NSCLC患者,分为A组55例和B组52例。A组给予埃克替尼+安罗替尼,B组给予埃克替尼+贝伐珠单抗。治疗1个周期后评价近期疗效。观察肿瘤标志物、不良反应,并随访2年。结果: A组、B组的客观缓解率分别为58.18%、63.46%,疾病控制率分别为89.09%、90.38%,差异均无统计学意义(P>0.05)。两组血清CA125、CEA、TPA、TK1、SCC-Ag、CYFRA21-1治疗前后差值比较差异无统计学意义(P>0.05)。A组与B组不良反应率比较无差异(P>0.05)。A组与B组的中位无进展生存期分别为17.3个月和18.1个月,两组无进展生存率比较差异无统计学意义(P>0.05)。结论: 埃克替尼联合安罗替尼或贝伐珠单抗治疗EGFR敏感突变晚期NSCLC的疗效和安全性相当。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：非小细胞肺癌, 表皮生长因子受体, 埃克替尼, 安罗替尼, 贝伐珠单抗

Abstract：Objective: To explore the efficacy and prognosis of erlotinib in combination with anlotinib or bevacizumab monoclonal antibody in the treatment of epidermal growth factor receptor (EGFR)-sensitive mutant advanced non-small cell lung cancer (NSCLC). Methods: A retrospective analysis was conducted on 107 patients with EGFR-sensitive mutant advanced NSCLC from September 2019 to February 2021, divided into Group A (55 cases) and Group B (52 cases). Group A received erlotinib + anlotinib, while Group B received erlotinib + bevacizumab. Short-term efficacy was assessed after one treatment cycle. Tumor markers, adverse reactions, and a 2-year follow-up were observed. Results: The objective response rate in Groups A and B was 58.18% and 63.46%, respectively, and the disease control rate was 89.09% and 90.38%, with no significant difference between the two groups (P>0.05). The differences in serum CA125, CEA, TPA, TK1, SCC-Ag, and CYFRA21-1 before and after treatment were not statistically significant (P>0.05). There was no significant difference in the incidence of adverse reactions between Groups A and B (P>0.05). The median progression-free survival in Groups A and B was 17.3 months and 18.1 months, respectively, with no statistically significant difference between the two groups (P>0.05). Conclusion: The efficacy and safety of erlotinib in combination with anlotinib or bevacizumab monoclonal antibody in the treatment of EGFR-sensitive mutant advanced NSCLC are comparable.

Key words： Non-small cell lung cancer Epidermal growth factor receptor Erlotinib Anlotinib Bevacizumab monoclonal antibody

基金资助:2020年度安徽省自然科学基金项目,(编号:2008085MF205)

通讯作者: 刘文静

引用本文:

李侠, 卢虎生, 刘坦, 孙雪竹, 刘文静. 埃克替尼联合安罗替尼或贝伐珠单抗治疗表皮生长因子受体敏感突变晚期非小细胞肺癌的效果及预后分析[J]. 河北医学, 2023, 29(12): 2083-2087.
LI Xia, LU Husheng, LIU Tan, et al. Efficacy and Prognostic Analysis of Erlotinib in Combination with Anlotinib or Bevacizumab Monoclonal Antibody in the Treatment of EGFR-sensitive Mutant Advanced NSCLC. HeBei Med, 2023, 29(12): 2083-2087.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2023.12.028 或 http://www.hbyxzzs.cn/CN/Y2023/V29/I12/2083